• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS’ Early-Stage CRO Reborn as Celerion

MDS’ Early-Stage CRO Reborn as Celerion

March 29, 2010
CenterWatch Staff

Part of MDS’ early-stage contract research organization (CRO), which was sold off in two parts earlier this month, is re-emerging as Celerion, a CRO owned by a group of private investors.

MDS completed the sale of its CRO division March 8 with part of the unit going to Ricerca Biosciences, an early-stage CRO in Concord, Ohio, and the other part going to a new corporation—announced today as Celerion—primarily owned by private investment firms Bain Capital Ventures and SV Life Sciences.

Celerion took over MDS’ development and regulatory services consultancy, as well as five early-stage facilities in Ireland, Nebraska, New Jersey, Arizona and Switzerland; and operations in Virginia and Canada.  Ricerca purchased MDS Pharma’s discovery through phase IIa operations in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

Although Celerion’s formal ties to MDS Pharma have been severed, the company said it remains committed to providing the same service for which MDS Pharma was known. Susan Thornton, Ph.D., formerly president of MDS Pharma’s late-stage clinical and central laboratory services business, will be the new CEO of Celerion.

“I'm energized by the prospect of taking this great business to the next level of market leadership,” she said in a statement. “Its combination of experienced people, scientific excellence, and state-of-the-art facilities constitutes a strong foundation for future growth. We look forward to continuing to provide our pharmaceutical, biotechnology and generic clients with leading early stage clinical research services. Like the company I am leading, my roots are in MDS Pharma Services.”

Celerion—a name derived from the Latin “celeratis,” meaning swiftness and speed—will focus on helping clients make informed go/no-go decisions on compounds in development as early as possible, according to a company release.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing